Navigation Links
RAND study finds evidence disease management programs
Date:12/10/2007

Disease management programs that help guide the care of patients with chronic health problems appear to improve the quality of health care, but there is little evidence that such efforts actually save money, according to a study issued today by the RAND Corporation.

The RAND Health study reviewed all past research on disease management programs, which seek to help patients with conditions like diabetes and congestive heart failure by offering a system of coordinated healthcare interventions. These interventions can range from pre-recorded telephone reminders to home visits by medical professionals.

Researchers selected 29 evaluations, systemic reviews and meta-analyses to focus on, covering 317 unique studies. That review found consistent evidence that these programs can improve health care quality, improve disease control, and, in the case of patients with congestive heart failure, reduce hospital admission rates. But patients with depression who were enrolled in disease management programs were more likely to use outpatient care and prescription drugs, increasing costs. There also is little evidence about whether these programs improve health outcomes over the long term.

Disease management is viewed as the silver bullet that can fix two problems of the health care system inadequate quality and high costs, said Soeren Mattke, lead author of the report and a senior natural scientist at RAND, a nonprofit research organization. Unfortunately, while there is evidence that disease management programs can indeed improve the quality of care, there is no conclusive evidence that they can actually save money.

Health insurance plans and employers nationally in 2005 spent about $1.2 billion on disease management programs, with 96 percent of the top 150 U.S. health insurance companies offering some form of disease management service. The topic also has become a key point in the national health care reform debate, as policymakers search for a way to improve health care quality and access, while controlling costs at the same time.

The RAND study analyzed research on various disease management programs and their effect on six chronic conditions: congestive heart failure, coronary artery disease, diabetes, asthma, depression and chronic obstructive pulmonary disease. With the exception of asthma and chronic obstructive pulmonary disease, which showed inconclusive results, researchers found consistent evidence that disease management programs did improve the quality of health care. There also was consistent evidence that patients with congestive heart failure and depression reported improved quality of life.

But evidence of cost-savings was inconclusive for most of the conditions, indicating that further research is needed. It is plausible that disease management programs reduce costs for congestive heart failure patients because many programs reduce hospital admissions for these patients, Mattke said. In contrast, research has shown that patients with depression are commonly under-treated, so a disease management program that actively screens for depression and encourages patients to get treatment will increase costs.

Most of the studies Mattke and his colleagues reviewed followed patients only for about a year, which is not long enough to assess long-term health outcomes. For example, a disease management program may improve a patients cholesterol levels in the short term, but it can take years to determine whether those interventions -- assuming they were sustained for a long period -- prevent heart attacks and costly hospitalizations years into the future.

People take for granted that these programs work and save money, because the concept is very plausible, Mattke said. But many things in medicine sound plausible until you do the research and find that promises dont hold true.

Health insurance plans, employers and policymakers also will have to evaluate whether the benefits of disease management programs are worthwhile, despite the lack of evidence for cost-savings, Mattke said.

Another factor is that disease management itself is not well-defined, Mattke said. The types of interventions can vary from congestive heart failure specialists at a local hospital hiring a nurse to educate patients about preventive care to large-scale programs reaching thousands of patients. Some programs may be better than others, but there has not been enough research to properly assess which ones are the most effective or what characteristics are associated with more successful programs.

Just because one type of intervention can benefit one disease, that doesnt mean it will work the same way for another disease, Mattke said. Most of the evidence for disease management comes from small provider-centered programs at academic medical centers or multi-specialty groups.

The study, Evidence for the Effect of Disease Management: Is $1 Billion a Year a Good Investment" will appear in the December issue of The American Journal of Managed Care. The other authors of the study are Michael Seid of Cincinnati Childrens Hospital, and Sai Ma of Johns Hopkins Bloomberg School of Public Health.


'/>"/>

Contact: Lisa Sodders
MEDIA@RAND.ORG
310-451-6913
RAND Corporation
Source:Eurekalert

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water soluble ... of Directors. Dr. Henig will bring a wealth of scientific experience in the food, ... Chief Technical and Scientific Officer of four major global companies in the last 4 ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical ... Physik Instrumente USA, have been selected as this year’s recipients of two top awards ... have been invited along with other honorees to accept their awards at a banquet ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... model aircraft flying hobbyists, and the University Aviation Association (UAA), the unifying voice ... The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through a STEM-based ...
(Date:6/22/2017)... Longmont, Colorado (PRWEB) , ... June 21, 2017 ... ... the RTP regional office in North Carolina, and engages Timothy Reinhardt to manage ... years of quality leadership at Pfizer Inc, with his most recent role as ...
Breaking Biology Technology: